Development · 9 Oct 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Dr Reddy’s Laboratories has received a Form 483 with two observations from the US Food and Drug Administration (USFDA) following an inspection at its manufacturing facility in Pydibhimavaram, Andhra Pradesh.
The United States Food and Drug Administration (USFDA) completed a PreApproval Inspection (PAI) at Dr Reddy’s Laboratories' FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, from October 5, 2026 to October 7, 2026, and issued a Form 483 with two observations.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.